Resumo

JAIMES, Fabián  e  DE LA ROSA, Gisela. Anticoagulation and sepsis: the opportunity for a new use of heparin?. Biomédica [online]. 2006, vol.26, n.1, pp.150-160. ISSN 0120-4157.

Sepsis is a leading cause of morbidity and mortality worldwide, and the magnitude of the problem seems higher in developing countries. In the last two decades the accepted standard treatment has resulted in only a slight decrease in mortality, and that decrease has been overshadowed by an almost 300% increase in incidence. Recently has been documented the close relationship between infection, inflammation and coagulation in sepsis has been documented; and although clinically overt disseminated intravascular coagulation may occur in only 30% to 50% of septic patients, the activation of the coagulation cascade is an early and common response to the infectious challenge. Moreover most of the molecules involved in the pro-coagulant state that characterizes sepsis are also powerful generators or amplifiers of the inflammatory response. These findings have fostered a comprehensive body of research regarding biological products with anticoagulant activity, as additional therapies for patients with the most severe states of the sepsis syndrome. This review explains the biological and molecular aspects that support the potential use of anticoagulant treatments in sepsis. Furthermore, we analyze the evidence provided by experimental and pre-clinical studies, which suggest the usefulness of heparin as an effective complementary treatment throughout the clinical stages of the disease.

Palavras-chave : sepsis; blood coagulation; inflammation; heparin; disseminated intravascular coagulation; shock; septic.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )